Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Semaglutide subcutaneous - CSPC ZhongQi Pharmaceutical Technology

Next Previous
X
Search
Drug Profile

Semaglutide subcutaneous - CSPC ZhongQi Pharmaceutical Technology

Alternative Names: HD-1916

Latest Information Update: 30 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSPC ZhongQi Pharmaceutical Technology
  • Class Antidementias; Antihypercalcaemics; Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Type 2 diabetes mellitus

Most Recent Events

  • 19 Sep 2024 CSPC Baike (Shandong) Biopharmaceutical plans a phase III trial for Obesity in December 2024 (SC, Injection) (NCT06604624)
  • 26 Aug 2024 CSPC ZhongQi Pharmaceutical Technology plans to launch semaglutide injection for Type 2 diabetes mellitus in 2026
  • 23 Feb 2024 Phase-III clinical trials in Type 2 diabetes mellitus (Adjunctive treatment) in China (SC) (NCT06161844)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top